@article{pmid37800356,

title = {Trajectories of opioid consumption as predictors of patient-reported outcomes among individuals attending multidisciplinary pain treatment clinics},

author = {A. Angarita-Fonseca and A. Lacasse and M. Choini\`{e}re and J. L. Kabor\'{e} and M. P. Sylvestre and G. D. Tchouangue Dinkou and J. Bruneau and M. O. Martel and R. Hovey and A. Motulsky and E. Rahme and M. G. Pag\'{e}},

doi = {10.1002/pds.5706},

issn = {1099-1557},

year  = {2023},

date = {2023-10-01},

urldate = {2023-10-01},

journal = {Pharmacoepidemiol Drug Saf},

abstract = {PURPOSE: This study aimed to identify opioid consumption trajectories among persons living with chronic pain (CP) and put them in relation to patient-reported outcomes 6 months after initiating multidisciplinary pain treatment.nnMETHODS: This study used data from the Quebec Pain Registry (2008-2014) linked to longitudinal Quebec health insurance databases. We included adults diagnosed with CP and covered by the Quebec public prescription drug insurance plan. The daily cumulative opioid doses in the first 6 months after initiating multidisciplinary pain treatment were transformed into morphine milligram equivalents. An individual-centered approach involving principal factor and cluster analyses applied to longitudinal statistical indicators of opioid use was conducted to classify trajectories. Multivariate regression models were applied to evaluate the associations between trajectory group membership and outcomes at 6-month follow-up (pain intensity, pain interference, depression, and physical and mental health-related quality of life).nnRESULTS: We identified three trajectories of opioid consumption: "no or very low and stable" opioid consumption (n = 2067, 96.3%), "increasing" opioid consumption (n = 40, 1.9%), and "decreasing" opioid consumption (n = 39, 1.8%). Patients in the "no or very low and stable" trajectory were less likely to be current smokers, experience polypharmacy, use opioids or benzodiazepine preceding their first visit, or experience pain interference at treatment initiation. Patients in the "increasing" opioid consumption group had significantly greater depression scores at 6-month compared to patients in the "no or very low and stable" trajectory group.nnCONCLUSION: Opioid consumption trajectories do not seem to be important determinants of most PROs 6 months after initiating multidisciplinary pain treatment.},

keywords = {Chronic Pain, Epidemiology, Pain Measurement, Patient-important outcome, Treatment},

pubstate = {published},

tppubtype = {article}

}

@article{pmid34724980,

title = {Patient-important outcomes reported in randomized controlled trials of pharmacologic treatments for COVID-19: a protocol of a META-epidemiological study},

author = {M. A. Jimenez-Mora and A. R. Varela and J. F. Meneses-Echavez and J. Bidonde and A. Angarita-Fonseca and R. A. C. Siemieniuk and D. Zeraatkar and J. J. Bartoszko and R. Brignardello-Petersen and K. Honarmand and B. Rochwerg and G. Guyatt and J. J. Yepes-Nu\~{n}ez},

url = {https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-021-01838-8, Systematic Reviews},

doi = {10.1186/s13643-021-01838-8},

issn = {2046-4053},

year  = {2021},

date = {2021-11-01},

urldate = {2021-11-01},

journal = {Syst Rev},

volume = {10},

number = {1},

pages = {289},

abstract = {BACKGROUND: The coronavirus disease 19 (covid-19) pandemic has underscored the need to expedite clinical research, which may lead investigators to shift away from measuring patient-important outcomes (PIO), limiting research applicability. We aim to investigate if randomized controlled trials (RCTs) of covid-19 pharmacological therapies include PIOs.



METHODS: We will perform a meta-epidemiological study of RCTs that included people at risk for, or with suspected, probable, or confirmed covid-19, examining any pharmacological treatment or blood product aimed at prophylaxis or treatment. We will obtain data from all RCTs identified in a living network metanalysis (NMA). The main data sources are the living WHO covid-19 database up to 1 March 2021 and six additional Chinese databases up to 20 February 2021. Two reviewers independently will review each citation, full-text article, and abstract data. To categorize the outcomes according to their importance to patients, we will adapt a previously defined hierarchy: a) mortality, b) quality of life/ functional status/symptoms, c) morbidity, and d) surrogate outcomes. Outcomes within the category a) and b) will be considered critically important to patients, and outcomes within the category c) will be regarded as important. We will use descriptive statistics to assess the proportion of studies that report each category of outcomes. We will perform univariable and multivariable analysis to explore associations between trial characteristics and the likelihood of reporting PIOs.



DISCUSSION: The findings from this meta-epidemiological study will help health care professionals and researchers understand if the current covid-19 trials are effectively assessing and reporting the outcomes that are important to patients. If a deficiency in capturing PIOs is identified, this information may help inform the development of future RCTs in covid-19.



SYSTEMATIC REVIEW REGISTRATIONS: Open Science Framework registration: osf.io/6xgjz .},

key = {Coronavirus, COVID-19, Patient-important outcome, Prevention, Reporting, Treatment},

keywords = {Coronavirus, COVID-19, Patient-important outcome, Prevention, Reporting, Respiratory system, Treatment},

pubstate = {published},

tppubtype = {article}

}